Jonathan Lim, M.D. (@JLimMD) header
Jonathan Lim, M.D. (@JLimMD) profile picture

MD-turned-entrepreneur seeking to revitalize people, planet & perspective through mission-driven companies in science (Erasca, ARCH) & the arts (City Hill Arts)

San Diego, CA
Joined January 2013
Photo by Jonathan Lim, M.D. (@JLimMD)Photo by Jonathan Lim, M.D. (@JLimMD)Photo by Jonathan Lim, M.D. (@JLimMD)Photo by Jonathan Lim, M.D. (@JLimMD)Photo by Jonathan Lim, M.D. (@JLimMD)Photo by Jonathan Lim, M.D. (@JLimMD)Photo by Jonathan Lim, M.D. (@JLimMD)Photo by Jonathan Lim, M.D. (@JLimMD)Photo by Jonathan Lim, M.D. (@JLimMD)Photo by Jonathan Lim, M.D. (@JLimMD)
Jonathan Lim, M.D. retweeted
Join us at #SITC2017 & see our poster on RNA-seq in TYRO3/AXL/MER (TAM) inhibition at 12:30pm & 6:30pm ET today. https://nitter.cf/t.co/OYgiOjNI7Y
Jonathan Lim, M.D. retweeted
At #SITC2017? See our poster on TYRO3/AXL/MER (TAM) as a novel #immunooncology target in #cancer 12:30pm & 6:30pm ET https://nitter.cf/t.co/OYgiOjNI7Y
3
7
Jonathan Lim, M.D. retweeted
Good news for NTRK+ NSCLC patients. We must search this oncogenic fussion and include it into the screening panels
1
20
2
25
Jonathan Lim, M.D. retweeted
Lost our amazing 27 yr old daughter to #lungcancer this year. Can't imagine 433 families a day dealing with the pain of this loss #433aday
10
30
5
48
Jonathan Lim, M.D. retweeted
Brain metastases occur in 20-40% of all patient with cancer. CNS-active treatments are urgently needed. #WCLC2017
Jonathan Lim, M.D. retweeted
ROS1 spotlight: #DYK ROS1 gene fusions are associated with #NSCLC & other #cancers? #PrecisionMedicine #WCLC2017
9
4
12
Jonathan Lim, M.D. retweeted
Very important observation that BRAF follows EGFR and ALK in being less responsive to immunotherapy despite higher smoker status nitter.cf/rdoebele/status/919757…
5
34
2
68
Jonathan Lim, M.D. retweeted
#CancerMoonshot calls for #clincialtrial designs that highlight patient engagement & improve #PrecisionMedicine https://nitter.cf/t.co/ObZfgfmmYM
4
1
Jonathan Lim, M.D. retweeted
It's #LungCancer Awareness Month! Check out @LUNGevity's chart on #NSCLC driver mutations, many of which are targeted by our pipeline. #LCAM
9
6
Watch: @VP Biden on the #CancerMoonshot initiative and the steps we're taking to put an end to cancer as we know it: go.wh.gov/gLjsES
33
154
9
445
Jonathan Lim, M.D. retweeted
#LCSM Chat topic 11/3: #LCAM—Pick Your Passion lcsmchat.com/2016/10/29/lcsm…
1
14
1
12
Jonathan Lim, M.D. retweeted
Brakes truly off for checkpoint inhibitors in NSCLC! Pembrolizumab now FDA approved firstline standard of care. reut.rs/2f3ZstR
1
4
6
Thanks to @BVBigelow from @Xconomy for visiting @Ignyta a few weeks ago. Check out his story about our science here: https://nitter.cf/t.co/oHNpTV6gsB
1
1
1
Jonathan Lim, M.D. retweeted
Want to learn about our #science? Check out @Xconomy's story for more on our #genomics analyses & #oncology approach https://nitter.cf/t.co/iHXeU2xbJx
1
2
"I must confess I’m a science geek. I’m a nerd. I won’t make any apologies for it" —@POTUS speaking at #WHFrontiers: frontiersconference.org
24
202
44
585
Jonathan Lim, M.D. retweeted
October is #BreastCancerAwarenessMonth! Check out @TIME to learn about the genetic drivers of #breastcancer ti.me/2dADydS #BCAM
Jonathan Lim, M.D. retweeted
ESMO 2016 Press Release: Single-Arm Trials Improve Early Access to Rare Cancer Drugs | ESMO esmo.org/Conferences/ESMO-20…
Jonathan Lim, M.D. retweeted
Original Article: Pembrolizumab or Chemotherapy in PD-L1–Positive Non–Small-Cell Lung Cancer (KEYNOTE-024) nej.md/2deKOuj #ESMO16
7
223
38
178